Navigating the Hot Topics landscape

Investors are making aggressive bets on the ability of early stage companies to deliver on the next generation of therapeutics and technologies. But advances in biology and novel technologies come with challenges ranging from unknown toxicities to complex manufacturing.

For our 25th anniversary NewsMakers, BioCentury has selected a slate of companies in “Hot Topic” areas such as immuno-oncology, regenerative medicine and rare diseases, as well as new modalities like the tumor microenvironment and modalities just coming of age such as cell and gene therapies and RNA-based therapeutics. ...